298 related articles for article (PubMed ID: 16466612)
1. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac.
Lindstrom R; Kim T
Curr Med Res Opin; 2006 Feb; 22(2):397-404. PubMed ID: 16466612
[TBL] [Abstract][Full Text] [Related]
2. Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye.
Chastain JE; Sanders ME; Curtis MA; Chemuturi NV; Gadd ME; Kapin MA; Markwardt KL; Dahlin DC
Exp Eye Res; 2016 Apr; 145():58-67. PubMed ID: 26474497
[TBL] [Abstract][Full Text] [Related]
3. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery.
Jones BM; Neville MW
Ann Pharmacother; 2013 Jun; 47(6):892-6. PubMed ID: 23715071
[TBL] [Abstract][Full Text] [Related]
4. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.
Heier JS; Awh CC; Busbee BG; Waterbury LD; Daniel P; Stoller GL; Cleary TS
Retina; 2009 Oct; 29(9):1310-3. PubMed ID: 19934822
[TBL] [Abstract][Full Text] [Related]
5. Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Retinal Diseases.
Rodrigues EB; Farah ME; Bottós JM; Bom Aggio F
Dev Ophthalmol; 2016; 55():212-20. PubMed ID: 26502088
[TBL] [Abstract][Full Text] [Related]
6. Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation.
Bucolo C; Marrazzo G; Platania CB; Romano GL; Drago F; Salomone S
J Pharm Pharmacol; 2014 Jul; 66(7):954-60. PubMed ID: 24697218
[TBL] [Abstract][Full Text] [Related]
7. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac.
Walters T; Raizman M; Ernest P; Gayton J; Lehmann R
J Cataract Refract Surg; 2007 Sep; 33(9):1539-45. PubMed ID: 17720067
[TBL] [Abstract][Full Text] [Related]
8. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers.
Ke TL; Graff G; Spellman JM; Yanni JM
Inflammation; 2000 Aug; 24(4):371-84. PubMed ID: 10850858
[TBL] [Abstract][Full Text] [Related]
9. A randomized comparison of to-aqueous penetration of ketorolac 0.45%, bromfenac 0.09% and nepafenac 0.1% in cataract patients undergoing phacoemulsification.
Bucci FA; Waterbury LD
Curr Med Res Opin; 2011 Dec; 27(12):2235-9. PubMed ID: 21992076
[TBL] [Abstract][Full Text] [Related]
10. Topical nepafenac as an alternate treatment for cystoid macular edema in steroid responsive patients.
Warren KA; Fox JE
Retina; 2008; 28(10):1427-34. PubMed ID: 18664937
[TBL] [Abstract][Full Text] [Related]
11. Effect of topical ketorolac 0.4%, nepafenac 0.1%, and bromfenac 0.09% on postoperative inflammation using laser flare photometry in patients having phacoemulsification.
Sahu S; Ram J; Bansal R; Pandav SS; Gupta A
J Cataract Refract Surg; 2015 Oct; 41(10):2043-8. PubMed ID: 26703278
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and patients' tolerability of Nepafenac and Ketorolac in the treatment of ocular inflammation following cataract surgery: A meta-analysis of randomized controlled trials.
Zhao X; Xia S; Wang E; Chen Y
PLoS One; 2017; 12(3):e0173254. PubMed ID: 28253334
[TBL] [Abstract][Full Text] [Related]
13. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy.
Gamache DA; Graff G; Brady MT; Spellman JM; Yanni JM
Inflammation; 2000 Aug; 24(4):357-70. PubMed ID: 10850857
[TBL] [Abstract][Full Text] [Related]
14. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Prospective randomized double-masked clinical trial.
Duong HV; Westfield KC; Chalkley TH
J Cataract Refract Surg; 2007 Nov; 33(11):1925-9. PubMed ID: 17964399
[TBL] [Abstract][Full Text] [Related]
15. Prostaglandin E2 inhibition of ketorolac 0.45%, bromfenac 0.09%, and nepafenac 0.1% in patients undergoing phacoemulsification.
Bucci FA; Waterbury LD
Adv Ther; 2011 Dec; 28(12):1089-95. PubMed ID: 22105509
[TBL] [Abstract][Full Text] [Related]
16. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery.
Lane SS; Modi SS; Lehmann RP; Holland EJ
J Cataract Refract Surg; 2007 Jan; 33(1):53-8. PubMed ID: 17189793
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ketorolac 0.4% and nepafenac 0.1% for the prevention of cystoid macular oedema after phacoemulsification: prospective placebo-controlled randomised study.
Tzelikis PF; Vieira M; Hida WT; Motta AF; Nakano CT; Nakano EM; Alves MR
Br J Ophthalmol; 2015 May; 99(5):654-8. PubMed ID: 25385061
[TBL] [Abstract][Full Text] [Related]
18. VITREOUS PROSTAGLANDIN E2 CHANGES AFTER TOPICAL ADMINISTRATION OF DICLOFENAC 0.1%, INDOMETHACIN 0.5%, NEPAFENAC 0.3%, AND BROMFENAC 0.09.
Pastore MR; De Giacinto C; Cirigliano G; D'Aloisio R; Addobbati R; Agostinis C; Radillo O; Di Martino G; Di Nicola M; Cecchini P; Tognetto D
Retina; 2020 Sep; 40(9):1838-1845. PubMed ID: 31800462
[TBL] [Abstract][Full Text] [Related]
19. Nepafenac dosing frequency for ocular pain and inflammation associated with cataract surgery.
Gow JA; Song CK; McNamara TR
J Ocul Pharmacol Ther; 2009 Aug; 25(4):385-6; author reply 386. PubMed ID: 19552601
[No Abstract] [Full Text] [Related]
20. [The opinion of the Expert Group of the Polish Society of Ophthalmology on using nepafenac in the prevention of postoperative macular edema after cataract surgery in diabetic patients].
Grabska-Liberek I; Bakunowicz-Łazarczyk A; Malukiewicz G; Misiuk-Hojło M; Mrukwa-Kominek E; Romaniuk W; Romanowska-Dixon B; Jurowski P; Kęcik D; Lubiński W; Omulecki W; Szaflik J; Szaflik JP; Pietruszyńska M; Karska-Basta I; Stafiej J; Gosławski W
Klin Oczna; 2016; 118(2):155-60. PubMed ID: 29912514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
